TPOXX

Indicated For

smallpox, mpox

About This Medication

# SIGA TPOXX Patient Assistance Guide: How to Get TPOXX (tecovirimat) at Low or No Cost **TPOXX (tecovirimat) is an antiviral medication developed by SIGA Technologies primarily for treating smallpox, with use in other orthopoxvirus infections like monkeypox under special protocols.** This guide explains access options, as SIGA does not currently offer a traditional patient assistance program (PAP) with public income-based eligibility or online applications. Instead, TPOXX is largely procured by governments for biodefense stockpiles and accessed through healthcare providers, CDC protocols, or emergency use.[1][3] ## About TPOXX (tecovirimat) TPOXX is a highly targeted antiviral that stops orthopoxviruses, such as smallpox and monkeypox (mpox), from spreading inside the body. It works by preventing viral particles from exiting infected cells, giving your immune system time to fight the infection.[1][3] - **FDA Approvals**: Oral capsules (for patients ≥13 kg) and IV injection (for patients ≥3 kg) are approved for smallpox treatment.[1] - **Monkeypox Use**: Not FDA-approved for mpox but available via CDC's expanded access investigational new drug (IND) protocol.[1] - **Global Status**: Approved for broader orthopoxviruses in EU, UK, Canada, Japan.[3][7] - **Safety**: Generally well-tolerated; common side effects include headache, nausea, fatigue. Recent trials (PALM007, STOMP, UNITY) confirmed safety similar to placebo, though efficacy for mpox needs further study.[5] TPOXX is not a routine prescription drug available at pharmacies. It's reserved for serious infections and distributed through government channels.[2][7] ## Who Qualifies for TPOXX Access? **Qualification is based on medical need, not income.** There is no standard SIGA PAP with income thresholds like 400-500% of the Federal Poverty Level (FPL) common in other programs. TPOXX access is for: - Patients with confirmed or suspected smallpox or orthopoxvirus infections (e.g., severe mpox).[1] - Those eligible under CDC IND for mpox.[1] - Pediatric patients meeting weight requirements.[1][6] - Patients unable to take oral form (IV option for severe cases).[1][8] Contact your doctor or local health department during outbreaks. The U.S. government maintains stockpiles via HHS/BARDA contracts.[2][7] ## Income Eligibility Breakdown No income requirements apply, as TPOXX is government-procured and free for eligible patients via public health systems. Here's a comparison to typical PAPs: | Household Size | Typical PAP (e.g., 400% FPL) | TPOXX Program | |---------------|------------------------------|---------------| | Individual | ~$60,000/year | No limit; medical need only | | Couple | ~$80,000/year | No limit; medical need only | | Family of 3 | ~$100,000/year | No limit; medical need only | | Family of 4 | ~$120,000/year | No limit; medical need only | *Notes*: FPL varies by year/location. TPOXX prioritizes outbreak response over financial screening.[1][2] ## Insurance Requirements **Insurance is not required.** TPOXX is provided at no cost through government programs (e.g., CDC, HHS stockpiles). Medicare, Medicaid, or private insurance do not cover it routinely, as it's not commercially marketed. During mpox outbreaks, it's distributed free via public health.[1][2][7] ## Step-by-Step Application Process No patient-direct application exists. Follow these steps: 1. **See Your Doctor**: Get diagnosed with smallpox/mpox or orthopoxvirus infection. Discuss TPOXX suitability.[1] 2. **Provider Requests Access**: Doctors request via CDC IND for mpox or contact SIGA/state health dept for smallpox.[1] 3. **Health Department Involvement**: Local/state CDC coordinates during outbreaks.[1] 4. **Approval**: CDC or HHS approves based on need (hours to days).[1] 5. **Receive Treatment**: Oral capsules or IV at hospital/clinic. No home delivery.[1][8] Call SIGA at (212) 672-9100 or visit www.siga.com for provider info. For mpox, call CDC hotline.[1] ## Timeline and Delivery - **Processing**: Emergency requests approved in 24-48 hours; routine via protocols.[1] - **Delivery**: Direct to healthcare facility from government stockpile. No patient shipping.[2] - **Treatment Duration**: Typically 14 days oral/IV.[4] ## Alternatives if Denied or Ineligible - **Vaccines**: JYNNEOS or ACAM2000 for prevention.[3] - **Supportive Care**: Pain relief, hydration, wound care for mpox.[4] - **Other Antivirals**: Cidofovir or brincidofovir (limited use, more side effects).[5] - **Clinical Trials**: Ongoing mpox studies (e.g., NIAID Phase III, ends mid-2025).[7] - **International**: EU/UK approvals for mpox; check local health authorities.[3][5] Consult your doctor for options. ## Disclaimer This guide is for informational purposes only and based on public data as of 2026. TPOXX access depends on outbreaks, protocols, and government policy. It is not medical advice. Consult healthcare providers or CDC for personalized guidance. SIGA disclaims liability. Efficacy for mpox is investigational; trials showed safety but mixed efficacy.[1][5] Always verify with official sources. (Word count: 912)

Program information last verified: March 30, 2026